RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia

Stock News

03/02

RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as "bad cholesterol" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1132294830"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132294830\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132294830?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 08:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132294830","market":"fut","top_or_hot":-1,"title":"RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia","media":"Stock News","content":"<p>RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as \"bad cholesterol\" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-02 08:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as \"bad cholesterol\" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1132294830","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132294830","pubTimestamp":1772410695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06938":"瑞博生物-B","BK4134":"信息科技咨询与其它服务","III":"信息服务"},"translate_title":"RIBOLIFE-B(06938)将于中国开始针对高脂血症的RBD7022注射液的III期试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1,"III":1},"content_text":"RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as \"bad cholesterol\" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}